此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Alveolar Ridge Splitting With Simvastatin/PRF Composite and Simultaneous Implant Placement (ARS-SIMV)

2026年7月2日 更新者:Maruwan Ali Alteer

Alveolar Ridge Splitting Augmented With Simvastatin/Platelet-Rich Fibrin Composite With Simultaneous Implant Placement in Horizontal Ridge Augmentation: A Randomized Controlled Clinical Trial

This randomized controlled clinical trial evaluated the effectiveness of platelet-rich fibrin (PRF) and a simvastatin/PRF composite combined with a xenogeneic bone graft during alveolar ridge splitting with simultaneous implant placement in patients with horizontal alveolar ridge deficiency. Twenty-one participants were randomly allocated into three groups: a control group receiving xenogeneic bone graft alone, a PRF group receiving xenogeneic bone graft blended with PRF, and a simvastatin/PRF group receiving xenogeneic bone graft blended with a simvastatin/PRF composite. Clinical and radiographic outcomes were assessed to compare horizontal and vertical bone gain, bone density, and keratinized tissue width after treatment.

研究概览

详细说明

Horizontal alveolar ridge deficiency frequently complicates implant placement following tooth loss. Alveolar ridge splitting is a well-established technique for horizontal ridge augmentation that allows simultaneous implant placement when sufficient vertical bone height is available. However, the predictability of bone regeneration may be influenced by the grafting material used.

Platelet-rich fibrin (PRF) is an autologous biomaterial rich in platelets, leukocytes, and growth factors that may enhance angiogenesis, soft tissue healing, and bone regeneration. Simvastatin has also demonstrated osteogenic and angiogenic properties through stimulation of bone morphogenetic protein-2 (BMP-2) expression and inhibition of osteoclastic activity. Combining simvastatin with PRF may further improve regenerative outcomes.

This single-center, randomized controlled clinical trial included 21 participants with horizontal alveolar ridge deficiency requiring implant-supported rehabilitation. Participants were randomly allocated into three equal groups (n = 7 per group). Group I underwent alveolar ridge splitting with simultaneous implant placement and augmentation using a xenogeneic bone graft. Group II received a xenogeneic bone graft blended with PRF. Group III received a xenogeneic bone graft blended with a simvastatin/PRF composite.

Clinical and radiographic evaluations were performed to assess horizontal bone gain, vertical bone gain, bone density using cone-beam computed tomography (CBCT), and keratinized tissue width. The study aimed to determine whether the addition of PRF alone or in combination with simvastatin could improve regenerative outcomes compared with conventional xenogeneic bone grafting.

研究类型

介入性

注册 (实际的)

21

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Giza Governorate
      • Cairo、Giza Governorate、埃及
        • Faculty of Oral and Dental Surgery, Misr University for Science and Technology

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

不

描述

Inclusion Criteria:

Horizontal alveolar ridge width of 3-5 mm. Vertical alveolar bone height of ≥11 mm. Edentulous site located in the mandibular anterior region. Absence of buccal bone undercuts. Male or female participants aged 18-50 years. Good general health and medically fit to undergo oral surgical procedures. Absence of periapical pathology at the intended implant site. Adequate crown height space to achieve a favorable crown-to-implant ratio. Willingness and ability to attend all scheduled follow-up visits. Provision of written informed consent.

Exclusion Criteria:

Uncontrolled systemic diseases (e.g., uncontrolled diabetes mellitus), active infection, bleeding disorders, or current anticoagulant therapy.

Severe systemic diseases (e.g., uncontrolled hypertension or severe cardiovascular disease).

Severe alveolar bone deficiencies not suitable for ridge splitting. Pregnancy or breastfeeding. Inability to comply with postoperative instructions or follow-up visits. Known allergy or hypersensitivity to simvastatin or study materials. Individuals from vulnerable populations unable to provide valid informed consent.

Bruxism or other parafunctional oral habits.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:control group
Participants underwent alveolar ridge splitting with simultaneous implant placement and augmentation using a xenogeneic bone graft.
Surgical expansion of the horizontally deficient alveolar ridge followed by immediate dental implant placement.
Xenogeneic bone graft used to augment the expanded alveolar ridge around the implant.
实验性的:PRF Group
Participants underwent alveolar ridge splitting with simultaneous implant placement and augmentation using a xenogeneic bone graft blended with platelet-rich fibrin (PRF).
Surgical expansion of the horizontally deficient alveolar ridge followed by immediate dental implant placement.
Xenogeneic bone graft used to augment the expanded alveolar ridge around the implant.
Autologous platelet-rich fibrin prepared from the participant's blood and blended with the xenogeneic bone graft.
实验性的:Simvastatin/PRF Group
Participants underwent alveolar ridge splitting with simultaneous implant placement and augmentation using a xenogeneic bone graft blended with a simvastatin/platelet-rich fibrin (PRF) composite.
Surgical expansion of the horizontally deficient alveolar ridge followed by immediate dental implant placement.
Xenogeneic bone graft used to augment the expanded alveolar ridge around the implant.
Autologous platelet-rich fibrin prepared from the participant's blood and blended with the xenogeneic bone graft.
Locally applied simvastatin incorporated into the PRF/xenogeneic bone graft composite to enhance bone regeneration.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Horizontal Bone Gain
大体时间:6 months after surgery
Horizontal bone gain was assessed by measuring the change in alveolar ridge width using cone-beam computed tomography (CBCT). Measurements were obtained by superimposition of preoperative and 6-month postoperative CBCT scans at standardized reference levels.
6 months after surgery
Vertical Bone Gain
大体时间:6 months after surgery
Vertical bone gain was assessed by comparing preoperative and 6-month postoperative CBCT scans using standardized reference points.
6 months after surgery

次要结果测量

结果测量
措施说明
大体时间
Bone Density
大体时间:6 months after surgery
Bone density of the augmented site was evaluated using CBCT gray scale values.
6 months after surgery
Keratinized Tissue Width
大体时间:Baseline and 6 months after surgery
Keratinized tissue width was measured clinically using a calibrated periodontal probe.
Baseline and 6 months after surgery
Implant Stability
大体时间:Baseline (immediately after implant placement) and 6 months after surgery.
Implant stability was assessed using the Implant Stability Test (IST) device. Measurements were recorded as IST values immediately after implant placement and at the 6-month follow-up.
Baseline (immediately after implant placement) and 6 months after surgery.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年6月2日

初级完成 (实际的)

2026年5月2日

研究完成 (实际的)

2026年5月30日

研究注册日期

首次提交

2026年7月2日

首先提交符合 QC 标准的

2026年7月2日

首次发布 (实际的)

2026年7月9日

研究记录更新

最后更新发布 (实际的)

2026年7月9日

上次提交的符合 QC 标准的更新

2026年7月2日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

There is no plan to share individual participant data (IPD) with other researchers. De-identified participant data will not be made publicly available. Study results will be disseminated through peer-reviewed publications and conference presentations.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅